Clinical Trials Directory

Trials / Completed

CompletedNCT00000223

Alternate-Day Buprenorphine Administration. Phase IV - 5

Alternate-Day Buprenorphine Administration. Phase IV

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
0 (planned)
Sponsor
National Institute on Drug Abuse (NIDA) · NIH
Sex
All
Age
20 Years – 49 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine if three times a subject's daily maintenance dose will hold for 72 hours without changes in agonist and antagonist effects.

Conditions

Interventions

TypeNameDescription
DRUGBuprenorphine

Timeline

Start date
1993-06-01
First posted
1999-09-21
Last updated
2005-06-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00000223. Inclusion in this directory is not an endorsement.

Alternate-Day Buprenorphine Administration. Phase IV - 5 (NCT00000223) · Clinical Trials Directory